PMC-403

N/A

Report date: 2023/05/24 14:39:30

Base Information

Drug NamePMC-403
Drug Alias NamePMC-403
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTEK receptor tyrosine kinase agonists
TargetsTEK receptor tyrosine kinase
Therapy Area/IndicationsSolid tumoursCapillary Leak SyndromeWet age-related macular degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPharmabcine
China Registration ClassN/A

Develop Information

Active CompaniesPharmAbcine IncPharmabcine
Inactive CompaniesN/A
Active IndicationsMacular Degeneration
Inactive IndicationsSolid tumoursCapillary Leak SyndromeWet age-related macular degeneration

Other Information

ATC CodeN/A
Related LinksN/A